Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the wide range of drugs potentially causing reversible or irreversible hair loss and emphasizes the difficulty of diagnosing drug-induced alopecia without withdrawal of the suspected medication; it reports no new clinical findings.

This report describes a patient experiencing hair repigmentation linked to adalimumab therapy, a TNF inhibitor, a phenomenon not previously associated with this class of drugs.

This case report observed that delirium can be the sole symptom of a stroke, as seen in an elderly patient with a thalamic hemorrhage, highlighting the need to consider stroke in the differential diagnosis when delirium is present without focal neurological signs.

This study found that 1 mg/day low-dose oral minoxidil significantly increased hair count compared to 0.25 mg/day over 24 weeks in women with female pattern hair loss, though no differences were observed in hair-shedding and quality-of-life scores between the two doses.

This case report details an atypical presentation of Hodgkin's lymphoma in an 87-year-old man, where severe hypercalcemia and mental status changes prompted further investigation and diagnosis.

This study found that DVd therapy is at least as effective as VAD/VAd for treating multiple myeloma and causes fewer side effects and reduced hospital visits.

This case report describes a boy with hypothalamic hamartoma experiencing pubertas precox and gelastic seizures, where leuprorelin therapy's effect on pubertas precox was controversial, but valproic acid effectively managed gelastic seizures.

This study reports an improvement in lymphomatoid papulosis type A in a 52-year-old patient who concurrently used hormone-replacement therapy.

This review discusses valproic acid as a common antiseizure medication associated with alopecia and highlights the need for its inclusion in relevant medical guides, without presenting new clinical findings.

In this study, stable types of leucoderma such as segmental vitiligo and piebaldism showed 100% repigmentation after melanocyte transplantation, suggesting surgery as the preferred method for these conditions.

This review found that laser-assisted drug delivery in humans was associated with several adverse effects, but no life-threatening events were reported in the studies examined.

In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.

This article provides no abstract or new findings and focuses on a patient registry related to spasticity care.

This study found that thalidomide increased peripheral lymphocyte counts and reduced inflammation in lupus erythematosus patients, but was associated with polyneuropathy, suggesting careful use in refractory cases.

This study found that administerating 10 mg/kg intramuscular fulvestrant did not stimulate hair regrowth in Pomeranian dogs with alopecia X, though higher doses may warrant further investigation.

This study reports that metreleptin treatment in a boy with congenital generalized lipodystrophy significantly improved metabolic complications and overall health outcomes during the first year of therapy.

This study found that deferoxamine may protect against sensorineural hearing loss by reducing oxidative stress-induced hair cell death through iron chelation and activation of the Nrf2 signaling pathway in lab models.

In this study, sustained-release sodium valproate showed high efficacy in achieving seizure remission for adults with focal and generalized epilepsy over one year, but side effects like weight gain and tremor were more frequent among heterozygous carriers of certain gene variants.

This study found no significant protective effect of coenzyme Q10 on hair loss from anthracycline antibiotics, although liver enzyme elevations were less frequent with CoQ10.

This study found that probiotics, specifically the L. plantarum MTCC 1325 strain, may have protective effects against Alzheimer's-like symptoms induced by D-Galactose in animal models, suggesting potential therapeutic use for neurodegenerative disorders.

This article discusses the development of targeted prodrug conjugates aimed at selectively attacking cancer cells while avoiding healthy ones, but reports no experimental results yet.

This study reports that periocular pigmentation may occur with the use of travoprost for treating alopecia areata of the eyelashes.

In this study, finasteride doubled the duration of the first off-cycle in intermittent androgen deprivation therapy for mice with LNCaP tumors but did not improve overall survival.

This study found that concentrations of haloperidol and its metabolite in human scalp hair significantly correlated with the daily dose and plasma trough levels in patients taking haloperidol.

In this study, researchers developed a novel method combining in silico and in vitro techniques to discover Aromoline, a potential osteoarthritis treatment that increases type II collagen expression in chondrocytes by targeting the dopamine receptor D4.

This case report from the University of Alabama, Birmingham describes a rare paradoxical reaction of increased agitation and hyperactivity in a patient with schizoaffective disorder treated with divalproex sodium.

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

This review highlights that Wedelolactone, a compound in Eclipta prostrata, appears to be a potent antioxidant and selective modulator of proteins linked to chronic diseases, suggesting further research into its pharmacological effects is warranted according to the examined data.

In this study, researchers assessed the effects of deferasirox in 85 children with ß-thalassemia in Kirkuk and reported that while 55.3% experienced a reduction in serum ferritin, 9.4% had adverse effects, indicating that deferasirox is generally well-tolerated as an iron chelator with modifiable side effects.